Short Interest in Apyx Medical Co. (NASDAQ:APYX) Decreases By 39.0%

Apyx Medical Co. (NASDAQ:APYX) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 140,500 shares, a decline of 39.0% from the October 31st total of 230,300 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average trading volume of 42,400 shares, the days-to-cover ratio is presently 3.3 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JMP Securities reaffirmed a “market perform” rating on shares of Apyx Medical in a research note on Monday, September 16th. BTIG Research started coverage on Apyx Medical in a research report on Thursday, October 17th. They set a “neutral” rating for the company. Finally, Craig Hallum raised Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th.

Institutional Investors Weigh In On Apyx Medical

Large investors have recently added to or reduced their stakes in the business. RPg Family Wealth Advisory LLC acquired a new position in Apyx Medical in the second quarter valued at approximately $101,000. Rathbones Group PLC lifted its position in shares of Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after acquiring an additional 150,000 shares during the period. Private Advisor Group LLC boosted its stake in Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after acquiring an additional 12,180 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Apyx Medical by 2.9% in the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after purchasing an additional 14,481 shares during the period. Finally, Royce & Associates LP increased its stake in Apyx Medical by 3.4% in the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock valued at $3,202,000 after purchasing an additional 85,267 shares in the last quarter. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Trading Down 4.7 %

Apyx Medical stock traded down $0.08 during mid-day trading on Friday, hitting $1.61. 64,749 shares of the stock were exchanged, compared to its average volume of 80,941. The firm’s fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $1.33. The company has a quick ratio of 4.52, a current ratio of 5.46 and a debt-to-equity ratio of 3.03. Apyx Medical has a 12 month low of $0.97 and a 12 month high of $2.80.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Friday, November 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. The business had revenue of $11.49 million for the quarter, compared to analyst estimates of $11.66 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. As a group, equities analysts predict that Apyx Medical will post -0.68 earnings per share for the current year.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.